Lead

Abhijit J Chaudhari, PhD

  • Core B Lead
  • Core B
Dr. Chaudhari is a Professor of Radiology in the School of Medicine. He directs the Center for Molecular and Genomic Imaging at UC Davis, which provides researchers with a range of imaging modalities that include MRI, PET, SPECT, CT, ultrasound, and optical imaging in both preclinical and clinical settings. He has helped develop novel medical imaging techniques for assessing neurological disease.

Angela Gelli, PhD

  • Project 2 Lead
  • Project 2
Dr. Angela Gelli is a Professor of Pharmacology in the School of Medicine. She is particularly interested in pathologies that impact the blood-brain barrier (BBB). Dr. Gelli has used in vitro models of the BBB as well as in vivo models to identify translational therapeutic targets.

Gene Gurkoff, PhD

  • Project 3 Lead
  • Project 3
Dr. Gene Gurkoff is an Associate Professor in the Department of Neurological Surgery in the School of Medicine. His research focuses on using advanced in-vivo electrophysiology techniques to identify systems-level changes in brain function with the goal of developing novel and innovative neuromodulatory approaches for treating patients suffering chronic cognitive deficits following traumatic brain injury or epileptic seizures.

Pamela J. Lein, PhD

  • CounterACT Director & Project 1 Lead
  • Project 1
Dr. Pamela Lein is a Professor of Neurotoxicology and Chair of Molecular Biosciences in the School of Veterinary Medicine. She has broad training and experience in molecular and cellular neurobiology, neuropharmacology and neurotoxicology. Her research focuses on defining the molecular and cellular mechanisms of neurotoxicology, including how chemical threat agents and therapeutic agents modulate neuroinflammation and neural function. 

Daniel Tancredi, PhD

  • Core C Lead
  • Core C
Dr. Tancredi is a Professor in the Department of Pediatrics. Dr. Tancredi contributes his statistical and data management expertise to the UC Davis CounterACT program by providing targeted statistical design and analysis support to the research projects and scientific cores and an integrated web-based research database system that is used to facilitate reliable and cost-efficient data capture, processing and sharing.

Heike Wulff, PhD

  • Core A Lead
  • Core A
Dr. Heike Wulff is Professor of Pharmacology in the School of Medicine. She has expertise in basic pharmacology, pharmacokinetics, drug development and medicinal chemistry and is particularly interested in potassium channel pharmacology and the design of new ion channel modulating drugs and tool compounds. 

Co-Lead

Amy Brooks-Kayal, MD, FAAN, FANA, FAES

  • CounterACT Co-Director and Project 1 Co-Lead
  • Project 1
Dr. Amy Brooks-Kayal is a Professor and Chair of Neurology in the School of Veterinary Medicine. Her research focuses on cellular and molecular pathways in the development of epilepsy following brain injury, with particular emphasis on identifying new therapies for the prevention and treatment of both seizures and cognitive co-morbidities characteristic of acquired epilepsy.

Marco Gonzalez, PhD

  • Project 2 Co-Lead
  • Project 2
Dr. Marco Gonzalez is an Associate Professor of Neurology in the School of Medicine. He is interested in developing new therapies that stop or prevent recurrent seizure episodes in epilepsy. He studies cellular and molecular mechanisms underlying epileptogenesis, particularly calpain dysregulation.  

Danielle Harvey, PhD

  • Core C Co-Lead
  • Core C
Dr. Harvey is Professor in the Division of Biostatistics, Department of Public Health Sciences. Her research primarily focuses on the statistical analysis of neuroimaging data to identify markers of disease progression. Dr. Harvey assists CounterACT investigators with study design, data analysis, and preparation of presentations and manuscripts.

Brad A Hobson, PhD

  • Core B Co-Lead
  • Core B
Dr. Brad Hobson is a Research Project Scientist at the Center for Molecular and Genomic Imaging at UC Davis. His research with the CounterACT program focuses on investigating the long term neurological consequences of acute organophosphate (OP) intoxication using in vivo imaging.